Thanks to Innovaderm's adaptive approach, we sailed through our
trial with ease!
“The team was not only knowledgeable but also innovative,
suggesting effective approaches to optimize resources and
streamline processes. Their flexibility and willingness to adapt
were invaluable, enabling us to navigate challenges and pivot when
necessary.”
Therapeutic Knowledge and
Experience in Rheumatology
+100
Established relationships with KOLs in 7 key countries in EU and NA
+1,000
Research sites by the end of Q4 2024
Leading Global CRO in Rheumatology and Dermatology
Why Trust Innovaderm for Your Rheumatology Trial?
INNOVADERM UNDERSTANDS
The Therapeutic Area
Geared with internal rheumatology experts with
+70 combined years of experience
Common grounds between dermatology and
rheumatology allowing us to apply our strong clinical, drug
development, regulatory and medical know-how
The Process
Fully established
European and North American operational teams and
cultivated partnerships with sites
Robust ties with top enrollers ensure
quality is never compromised
The Industry
Our organization is led by researchers, with a
core focus on science and innovation that permeates every
aspect of our work.
We are the only niche CRO in rheumatology and dermatology
As a strong and established mid-size CRO, we listen to your needs,
provide you with a personalized approach, and we nurture long-time
relationships.
2024 CRO Leadership Awards
4 Consecutive Years
Therapeutic Knowledge and Experience in 30+ Indications
Deep rheumatology insight to operationalize and execute
MEET SOME OF OUR KEY RHEUMATOLOGY TEAM MEMBERS
Pavle Vukojevic, MD, MSc
Rheumatologist - Specialist of Internal Medicine
Dr. Vukojevic has over 25 years’ experience in clinical development within the CRO
industry and over 10
years of clinical/academic practice in rheumatology. He is an experienced clinical development executive at
global level with extensive knowledge of international drug development processes and procedures (phases
I-IV). He is the author of “Conducting Clinical Trials in Europe: An Insider’s Analysis” expert report
(edition Insight Pharma Reports for the Cambridge Healthtech Institute).
Eugene Uy, MD
Medical Monitor
Dr. Uy is a trained physician who specializes in rheumatology, osteoporosis, internal
medicine and clinical
immunology. With over a decade of experience in rheumatology research, Dr. Uy oversees global clinical
studies.
Kristen Neely
Clinical Trial Manager
Accomplished CTM with 35 years of experience, Kristen has experience in all phases of
clinical research.
Her roles have ranged from coordinator and associate to mentor, trainer, and consultant,
specializing in
rheumatology. Kristen has been a part of Dr. Daniel Furst's team, a KOL in rheumatoid diseases.
Nalanie Johnson, BSc, PMP
Project Manager
Nalanie Johnson, with a BSc in Human Biology and a postgraduate certificate in clinical research,
specializes in rheumatology trials. With over 10 years of experience in the field, she has
effectively
managed research plans and optimized recruitment for numerous organizations.
Bhaskar Srivastava
Senior Vice President of
Clinical Development
Nimbus Therapeutics www.nimbustx.com
Innovaderm has the right experience, the right team and the right philosophy.
"With the powerful combination of rigor & innovation that their team brings, we were able to execute our
study smoothly and deliver results showing profound potential for patients."
CASE STUDY - SYSTEMIC SCLEROSIS
Study Characteristics & Challenges
Disease Focus: Systemic Sclerosis (SSc), including subgroups Raynaud’s Phenomenon
(RP), Limited
cutaneous SSc (lcSSc), and Diffuse cutaneous SSc (dcSSc).
Patient Demographics: 49 patients enrolled, with a diverse geographic distribution due
to the rarity of
the condition.
Study Design: Biopsy-based research requiring 2 or 4 x 3mm biopsies per patient; no
treatment was
offered as part of the study.
Recruitment Challenge: The lack of treatment provision made the study less appealing
for recruitment, compounded by the logistical challenges of coordinating transport and clinic visits for
distant patients.
Success Factors & Strategies
Timely Recruitment: Despite longer timelines associated with local academic sites and
the institutional
burden, patient recruitment was completed on schedule without any advertisement.
Low Discontinuation Rate: The study achieved a remarkably low patient discontinuation
rate of only 4%.
Effective Coordination: Successful management of the logistical complexities involved
in transporting
patients from various locations to the clinic.
Results
High retention rate with a mere 4% discontinuation, our study design and patient management strategies have
proven to be effective
CRO requires experienced staff in immunology and inflammation related diseases. For few diseases, it
requires cross-functional expertise in areas such as dermatology & rare diseases.
Infrastructure
It is important to have a solid infrastructure, including a network of clinical sites and robust
information systems, to conduct rheumatology trials effectively.
Regulations
It is essential for CROs to possess a comprehensive understanding and experience with the rheumatology
endpoint guidelines set forth by the American College of Rheumatology. This includes familiarity with
ACR20, ACR50, ACR7, DAS28, and other pertinent regulations.
Risks
Recruiting eligible participants may be more difficult due to higher competitive intensity. Shortage of
rheumatology experts will be a key challenge.
Your Niche Rheumatology CRO.
Let’s Talk!
Connect With Us!
"As a strong and established niche CRO, we listen to your needs, provide you with a personalized approach,
and nurture long-time relationships. Reach out to see how Innovaderm is expanding into rheumatology."
"*" indicates required fields
"*" indicates required fields
We use cookies to ensure the best user experience on our website. By pursuing your navigation, you consent to the use of these cookies. You can decline by changing your preferences in your browser's settings; however, your user experience may be lessened.
AcceptLearn more